ReviewBiomedicines2026
Stem Cell Therapies for Gastrointestinal and Liver Diseases: Translational Barriers, Clinical Heterogeneity, and Future Directions.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Gastrointestinal and liver diseases remain major contributors to global morbidity and mortality, with limited options for curative or regenerative treatment. Innovative cell-based platforms for liver regeneration and treatment include advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and organoids produced by them, while cell-free systems like extracellular vesicles (EVs) offer a new approach to restore tissue function and homeostasis. This review summarizes key advances from 2020 to 2025 in the translational development of these platforms. MSCs have achieved clinical validation in perianal Crohn's disease and show encouraging antifibrotic and immunomodulatory effects in cirrhosis and acute-on-chronic liver failure. iPSC and iPSC-derived organoids now enable disease modeling and, in early trials, have shown direct epithelial repair. Emerging cell-free approaches based on EVs promise safer, scalable products. Despite rapid progress, challenges remain in potency standardization, manufacturing, and long-term efficacy assessment. International harmonization through the EMA, FDA, and PMDA frameworks is accelerating the translation of stem cell-based advanced therapy medicinal products. The integration of bioengineering, data science, and ethical governance will determine whether these regenerative approaches evolve into accessible standard-of-care interventions for gastrointestinal and hepatic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.